NCCN VERSION 2 2015

144 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-69
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
subsequent excision. Am J Clin Pathol 2006;126:310-313. Available at:
.
31. Nagi CS, O'Donnell JE, Tismenetsky M, et al. Lobular neoplasia on
core needle biopsy does not require excision. Cancer 2008;112:2152-
2158. Available at:
32. Hwang H, Barke LD, Mendelson EB, Susnik B. Atypical lobular
hyperplasia and classic lobular carcinoma in situ in core biopsy
specimens: routine excision is not necessary. Mod Pathol
2008;21:1208-1216. Available at:
.
33. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated
when breast core needle biopsies show atypical lobular hyperplasia or
lobular carcinoma in situ: a correlative study of 33 patients with review
of the literature. Am J Surg Pathol 2005;29:534-543. Available at:
.
34. Karabakhtsian RG, Johnson R, Sumkin J, Dabbs DJ. The clinical
significance of lobular neoplasia on breast core biopsy. Am J Surg
Pathol 2007;31:717-723. Available at:
.
35. O'Neil M, Madan R, Tawfik OW, et al. Lobular carcinoma in
situ/atypical lobular hyperplasia on breast needle biopsies: does it
warrant surgical excisional biopsy? A study of 27 cases. Ann Diagn
Pathol 2010;14:251-255. Available at:
.
36. Foster MC, Helvie MA, Gregory NE, et al. Lobular carcinoma in situ
or atypical lobular hyperplasia at core-needle biopsy: is excisional
biopsy necessary? Radiology 2004;231:813-819. Available at:
.
37. Hussain M, Cunnick GH. Management of lobular carcinoma in-situ
and atypical lobular hyperplasia of the breast--a review. Eur J Surg
Oncol 2011;37:279-289. Available at:
.
38. Rendi MH, Dintzis SM, Lehman CD, et al. Lobular in-situ neoplasia
on breast core needle biopsy: imaging indication and pathologic extent
can identify which patients require excisional biopsy. Ann Surg Oncol
2012;19:914-921. Available at:
.
39. Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the
management of lobular neoplasia. J Natl Compr Canc Netw
2006;4:511-522. Available at:
.
40. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker
expression and risk of subsequent tumors after initial ductal carcinoma
in situ diagnosis. J Natl Cancer Inst 2010;102:627-637. Available at:
.
41. Stackievicz R, Paran H, Bernheim J, et al. Prognostic significance of
HER-2/neu expression in patients with ductal carcinoma in situ. Isr Med
Assoc J 2010;12:290-295. Available at:
.
42. Zhou W, Jirstrom K, Johansson C, et al. Long-term survival of
women with basal-like ductal carcinoma in situ of the breast: a
population-based cohort study. BMC Cancer 2010;10:653. Available at:
.
43. Lari SA, Kuerer HM. Biological Markers in DCIS and Risk of Breast
Recurrence: A Systematic Review. J Cancer 2011;2:232-261. Available
at:
44. Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure
ductal carcinoma in situ: a prospective observational study. Lancet
2007;370:485-492. Available at:
.